The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
DRUG

alpha-1 proteinase inhibitor (human)

60 mg/kg weekly for 20 weeks

Trial Locations (10)

10019

St Lukes-Roosevelt Hospital Center, New York, New York

19140

Temple University Hospital, Philadelphia

29425

Medical University of South Carolina, Charleston

33101

University of Miami School of Medicine, Miami

44122

Cleveland Clinic Foundation, Cleveland

80206

National Jewish Medical and Research Center, Denver

32610-0225

University of Florida College of Medicine, Gainesville

75708-3154

University of Texas Health Center at Tyler, Tyler

CB2 2XY

University of Cambridge - Cambridge Institute for Medical Research, Cambridge

EH8 9AG

University Teaching Hospital of Edinburgh, Edinburgh

Sponsors
All Listed Sponsors
lead

Grifols Therapeutics LLC

INDUSTRY